Mega-Alpha (Alfacalcidol)

Alfacalcidol is converted in the liver to calcitriol, the active form of vitamin D. Calcitriol binds to vitamin D receptors in intestinal cells, increasing the synthesis of calcium‑binding proteins, which boosts calcium and phosphate absorption from the gut and influences bone remodeling.

The dose of Mega-Alpha is individualized by a qualified prescriber based on the patient’s clinical condition, laboratory values, and response to therapy. Healthcare professionals determine the appropriate strength and frequency according to current medical guidelines.

Safety data for alfacalcidol in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by a treating physician.

To request Mega-Alpha, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Alfacalcidol differs from calcitriol in that it requires hepatic conversion before becoming active, which may provide a more gradual rise in calcium levels. This can be advantageous in patients with fluctuating calcium needs, while calcitriol acts directly and may be preferred when rapid correction is required.

Store Mega-Alpha at temperatures below 25 °C, in its original packaging, and protect it from moisture and direct sunlight. Keep the product out of reach of children and avoid exposing it to excessive heat or humidity.

Mega-Alpha is taken orally, usually with or without food as directed by the prescriber. The tablet should be swallowed whole with water and not chewed or crushed unless specifically instructed.

The most serious risks include hypercalcemia and hyperphosphatemia, which can lead to kidney stones, vascular calcification, or cardiac arrhythmias. Patients should be monitored for symptoms such as nausea, weakness, confusion, or irregular heartbeat and have laboratory tests performed regularly.

Mega-Alpha should be avoided in individuals with known hypersensitivity to alfacalcidol or any excipients, in patients with uncontrolled hypercalcemia, and in those with severe renal failure where calcium balance cannot be safely monitored.